ClinicalTrials.gg
Not yet recruitingNCT07124793Updated Aug 15, 2025

A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors

A Phase 2 interventional study of IBI363+IBI305 in EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-15.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 106 studies testing bevacizumab in Ovarian Neoplasms — 22 open to participants now, 32 under way, 9 of them phase 3. Bevacizumab · Ovarian Neoplasms.

Planned enrollment
48th of 106
60 · median 52
Started
2025
with 8 others
Phase 2
66 of 106
11 open now
Primary completion
2026-09
later than 10 of 31 live
Registered
98th of 106
by date

Among the 106 studies testing bevacizumab in Ovarian Neoplasms, this one is the 48th largest by planned enrollment, is one of 9 that started in 2025, is one of 66 in phase 2, reaches primary completion later than 10 of the 31 other live ones, and was the 98th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

22 of the 106 studies testing bevacizumab in Ovarian Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies testing bevacizumab in Ovarian Neoplasms, or all of them as a file.
02

Study summary

CIBI363A203, a Phase 2 study to evaluate the safety, tolerability and preliminary efficacy of IBI363 combined with IBI305 (a bevacizumab biosimilar) in participants with advanced malignancies conducted in China. Primary endpoint is objective response rate (ORR) per RECIST v1.1. Secondary endpoints include DoR, DCR, TTR, PFS, per RECIST v1.1, and OS; the incidence and severity of AEs, irAEs, SAEs, AESIs and their relationship to the investigational drug, and changes in vital signs, physical examination, and laboratory values before and after study treatment; PK, and immunogenicity of IBI363. The cohorts include: IBI363 and IBI305 combination therapy in participants with advanced EGFRmut NSCLC progressed after EGFR TKI and Platinum-based chemotherapy, and advanced platinum-resistant ovarian cancer (PROC). The anticipated enrollment for this study is approximately 60 participants with each cohort 30 participants, and actual enrollment may change with future amendments as cohorts are opened and closed based on evolving data.

03

Conditions studied

  • EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet all of the following inclusion criteria to be enrolled in the study:

  1. Sign the written form and be able to comply with the visit arrangements and related procedures specified in the protocol.
  2. Aged >= 18 years and \<= 75 years, regardless of gender.
  3. Performance Status (ECOG PS) score of 0 or 1.
  4. Expected survival time >= 3 months.
  5. Locally advanced or solid tumors confirmed by histology or cytology that are inoperable and cannot receive radical concurrent radiotherapy and chemotherapy:
  6. Cohort A (EGFR-mutated NSCLC):

    • or cytologically confirmed unresectable locally advanced or metastatic non-small cell lung cancer;
    • Documented EGFR mutation (ex19del or L858R) detected in tumor tissue or blood samples;
    • Have progressed on or are intolerant to at least 1 prior line of approved EGFR TKI for metastatic or locally advanced NSCLC.T790M mutation requires 3rd generation TKI;
    • Patients with metastatic or locally advanced NSCLC who have shown progression or intolerance after at least 1 line of platinum-based chemotherapy;
    • Intolerance to or progression of the most recent line of anti-tumor therapy.
  7. Cohort B (PROC):

    • Histologically or cytologically confirmed locally advanced unresectable or metastatic ovarian cancer, primary peritoneal cancer, or fallopian tube cancer;
    • Subjects with a documented breast cancer gene (BRCA) mutation (germline and/or somatic) must have been previously treated with a poly(ADP-ribose) polymerase (PARP) inhibitor;
    • For subjects with documented positive folate receptor-α (FRα) expression in tumor tissues, they should have previously received mirvetuximab soravtansine (MIRV) or ADC drugs with the same target, and have radiologically or pathologically confirmed PD;
    • Patients who have previously received ≥ 1 line of platinum-based chemotherapy and experienced progressive disease;

      • If you have only received 1 line of platinum-based chemotherapy, you must have received at least 4 cycles of platinum-based therapy, the best response is PR or CR, and disease progression occurs > 3 months and \< 6 months after the last platinum-based chemotherapy;
      • If receiving 2 or more lines of platinum-based chemotherapy, must have had disease progression during or \< 6 months after the last line of platinum-based chemotherapy Note: Disease progression is confirmed by imaging or pathology.
    • Must have received at least 1 line of prior systemic anti-cancer therapy:

      • Adjuvant ± therapy is considered as systemic anti-tumor treatment;
      • Maintenance therapy [e.g., bevacizumab and PARP inhibitors] as part of front-line anti-tumor treatment (the number of lines will not be counted separately);
      • For a change in treatment regimen, if the changed therapeutic drug is the same type of drug as the previous first-line treatment (for example, platinum, taxane, anthracycline, PARP inhibitor, etc. before and after the change), and there is no imaging disease progression before the change in therapeutic drug, the changed therapeutic regimen will be considered as part of the number of lines of treatment as before and will not be counted separately;
      • If the changed therapeutic drug is a different type of drug from the previous first-line treatment, or if radiographic disease progression occurs before the change of treatment, the number of lines needs to be calculated separately.
  8. Adequate bone marrow and organ function:

    • (ANC) ≥ 1.5 × 109/L; eosinophils \< 1.5 × (ULN); count (PLT) ≥ 100 × 109/L; ≥ 9.0 g/dL; have not received treatment with erythropoietin (EPO), granulocyte-colony stimulating factor (G-CSF), or granulocyte-macrophage colony stimulating factor (GM-CSF) within 14 days prior to the first dose, and have not received blood transfusion (including red blood cell and platelet transfusion) within at least 14 days;
    • Liver function: total ≤ 1.5 × ULN; and ALT ≤ 2.5 × ULN, without liver metastasis (if liver metastasis is present, ≤ 5 × ULN); albumin ≥ 3.0 g/dL (without albumin infusion within 14 days before the first dose);
    • Renal function: serum creatinine ≤ 1.5 × ULN, or ≥ 60 mL/min (using Cockcroft-Gault formula [Appendix 4]); and urine protein \< 2+ or total 24-h urine protein \< 1 g;
    • Coagulation function: (INR) ≤ 1.5; activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN (subjects receiving anticoagulant therapy with coagulation function within the above range are allowed to be enrolled);
  9. At least one according to v1.1.
  10. For female subjects of childbearing age, a negative urine or serum pregnancy test within 7 days prior to receiving the first study drug administration. If the urine pregnancy test result is positive, a blood pregnancy test is required to be clearly negative or not pregnant;

Exclusion criteria

Exclusion Criteria:

  1. Cohort B (PROC) should not be enrolled if any of the following criteria is met based on histological or cytological findings:

    1. Documented sarcoma, mucinous carcinoma, undifferentiated carcinoma, or a combination thereof;
    2. Confirmed low-grade or borderline tumors, or contains the above components.
  2. Previously received IL-2/IL-15 cytokine therapy. Except for the use of IL-2/IL-15 as an adjuvant component of adoptive cell therapy or as an immunomodulatory therapy for subjects.
  3. Excluded medications and other treatments (subjects should not receive any of the following treatments):

    • Have received small-molecule targeted therapy or oral chemotherapy within 2 weeks or 5 half-lives (whichever is longer) before the first dose of the study drug; have received intravenous infusion of chemotherapy drugs within 3 weeks before the first dose of the study drug; have received Chinese herbal medicines with anti-tumor indications within 2 weeks before the first dose of the study drug;
    • Nitrosourea antineoplastic agents and mitomycin C within 6 weeks prior to the first dose of study drug;
    • Use of any antibody-based anti-tumor therapy within 4 weeks prior to the first dose of the study drug;
    • Participation in any medical device or other therapeutic interventional clinical trial within 2 weeks prior to the first dose of study drug;
    • Palliative radiotherapy within 2 weeks prior to the first dose of the product, or radical radiotherapy within 4 weeks prior to the first dose;
    • Received adoptive cell therapy within 8 weeks prior to the first dose of study drug;
    • Use of against infectious disease prophylaxis within 4 weeks prior to the first dose of study drug.
  4. Active or untreated central nervous system (such as brain or ) confirmed by imaging assessment during screening or previous imaging assessment.

    • Subjects with asymptomatic (i.e., no neurologically relevant symptoms, no treatment is required, and the diameter of metastatic lesions is ≤ 1.5 cm) may participate in this study.
    • Subjects whose symptoms of brain metastases are stable for ≥ 4 weeks after treatment and whose brain metastases do not increase in number or further increase after the end of treatment may participate in this study as long as they meet all of the following criteria:

      • outside the central nervous system;
      • No metastases to meninges, midbrain, pons, medulla oblongata, or spinal cord; no multiple cerebellar metastases;
      • No compression of the aqueduct of the midbrain, no compression of the third or fourth ventricle, and no spinal cord compression;
      • Hormone therapy is discontinued 14 days prior to the first dose of the study drug.

    Note: Central nervous system lesions are not considered target lesions.

  5. The tumor invades surrounding important tissue structures (such as mediastinal great vessels, superior vena cava, inferior vena cava, pericardium, heart, trachea, esophagus, etc.) or has the risk of gastrointestinal/respiratory fistula.
  6. The subject has a history of significant toxicity related to administration and requires permanent discontinuation of the treatment.
  7. Subjects with adverse reactions related to any previous anti-tumor treatment that have not recovered to Grade 0-1; except for persistent Grade 2 alopecia, peripheral neuropathy, hypomagnesemia, toxicities that are expected to be unrecoverable but stably controlled by the drug, and other conditions that the investigator considers to have no safety risk.
  8. Have not recovered sufficiently from previous surgery, or have undergone any major surgery within 4 weeks prior to the first dose of the study drug.
  9. Cardiovascular and cerebrovascular diseases with significant clinical significance, including:

    • Ventricular arrhythmia or other uncontrolled arrhythmias requiring medical intervention, such as antiarrhythmic drug therapy, etc.;
    • Severe conduction disorders (e.g., 3rd degree atrioventricular block);
    • HR- interval (QTc interval, calculated using the Fridericia method [Appendix 5]) ≥ 480 ms;
    • Uncontrolled hypertension (SBP ≥ 160 mmHg or DBP ≥ 100 mmHg) despite of standard treatment;
    • History of myocarditis;
    • Congestive heart failure currently requiring treatment;
    • (LVEF) \< 50%;
    • Class III or IV cardiovascular disease according to (NYHA) functional classification;
    • History of acute coronary syndrome (including myocardial infarction and unstable angina), coronary angioplasty or stenting within 6 months prior to the first dose of the study drug;
    • History of any arterial thromboembolic events within 6 months prior to the first dose of study treatment, including myocardial infarction, unstable angina, cerebrovascular accident, etc.
    • History of deep vein thrombosis, pulmonary embolism, or any other serious thromboembolic event within 3 months prior to the first dose of study drug (thrombus or catheter-derived thrombus caused by an implanted venous port or superficial venous thrombosis is not considered a serious thromboembolism).
    • Known active seizures.
  10. Subjects with interstitial pneumonia requiring steroid hormones or other treatments, or a history of other lung diseases (such as pulmonary fibrosis, pneumoconiosis, interstitial lung disease, non-infectious pneumonia), or uncontrolled lung diseases (such as pulmonary fibrosis, severe radiation pneumonitis and acute lung injury) or suspected of having such diseases through imaging examinations during the screening period.
  11. Allergic constitution, asthma, history of atopic dermatitis.
  12. Pleural effusion, abdominal effusion or pericardial effusion requiring drainage or with obvious symptoms.
  13. Active diseases requiring systemic treatment (such as the use of disease-modifying drugs, corticosteroids or immunosuppressants) occurred within 2 years before the first administration. Alternative therapies (such as thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency, etc.) are not considered systemic treatments.
  14. Have used immunosuppressive drugs within 14 days before the first study treatment, excluding intranasal and inhaled corticosteroids, or use systemic corticosteroids with a dose of less than 10 mg/day prednisone (or other corticosteroids with an equivalent dose to 10 mg/day prednisone), or use corticosteroids to prevent allergy to contrast agents.
  15. Known allogeneic organ transplantation;
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    platinum resistant ovarian cancer

    Drug: IBI363+IBI305

  • Experimental
    EGFR mutant NSCLC cohort

    Drug: IBI363+IBI305

Interventions

  • DrugIBI363+IBI305

    Drug pages: Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363 · Bevacizumab

    Each treatment cycle lasts for 21 days (the first treatment cycle is 28 days). Subjects will receive IBI363 Q3W in combination with bevacizumab Q3W until 2 years of treatment, PD, intolerable toxicity, start of new anti-tumor treatment, withdrawal of informed consent, death, or study termination (whichever occurs first).

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    Time frame: Through out the study (up to 2 years)

Secondary outcomes

  1. disease control rate (DCR)

    To evaluate the preliminary antitumor activity of IBI363 plus bevacizumab.

    Time frame: Through out the study (up to 2 years)

  2. duration of response (DoR)

    To evaluate the preliminary antitumor activity of IBI363 plus bevacizumab.

    Time frame: Through out the study (up to 2 years)

  3. time to response (TTR)

    To evaluate the preliminary antitumor activity of IBI363 plus bevacizumab.

    Time frame: Through out the study (up to 2 years)

  4. progression-free survival (PFS)

    To evaluate the preliminary antitumor activity of IBI363 plus bevacizumab.

    Time frame: Through out the study (up to 2 years)

  5. Overall survival (OS)

    To evaluate the preliminary antitumor activity of IBI363 plus bevacizumab.

    Time frame: Through out the study (an average of 2 years)

  6. Adverse Enent (AE)

    AE is defined as an unexpected medical problem that happens during treatment with a drug or other therapy.

    Time frame: Up to 90 days after the last administration

  7. Treatment-Emergent AE (TEAE)

    A TEAE will be defined as any new AE that begins, or any pre-existing condition that worsens in severity, after at least 1 dose of study treatment has been administered.

    Time frame: Up to 90 days after the last administration

  8. Immune-related AE (irAE)

    irAE is defined as all grades of adverse drug reactions in clinical trials of anti-tumor drugs/therapies that are determined to be causally related to immune mechanisms.

    Time frame: Up to 90 days after the last administration

  9. Adverse Event of Special Interest (AESI)

    AESI (Adverse Event of Special Interest) refers to adverse events that require special close monitoring to enhance the understanding of the investigational drug's safety. AESIs may be non-serious events.

    Time frame: Up to 90 days after the last administration

  10. Serious Adverse Event (SAE)

    An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or is an important medical event that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before.

    Time frame: Through out the study (up to 2 years)

  11. Plasma concentration (Cmax) of IBI363

    PK parameters to be evaluated for IBI363 including maximum concentration (Cmax) will be determined when appropriate.

    Time frame: Up to 2 years

  12. Area under the curve (AUC) of IBI363

    PK parameters to be evaluated for IBI363 including area under the curve (AUC) will be determined when appropriate.

    Time frame: Up to 2 years

  13. Half-life (T1/2) of IBI363

    PK parameters to be evaluated for IBI363 including half-life (t1/2) will be determined when appropriate.

    Time frame: Up to 2 years

  14. Clearance (CL) of IBI363

    PK parameters to be evaluated for IBI363 including clearance (CL) will be determined when appropriate.

    Time frame: Up to 2 years

  15. Volume of distribution (V) of IBI363

    PK parameters to be evaluated for IBI363 including volume of distribution (V) will be determined when appropriate.

    Time frame: Up to 2 years

  16. Immunogenicity of IBI363

    Each subject will be tested for anti-drug (IBI363) antibody (ADA), and ADA-positive serum samples will continue to be tested for neutralizing antibodies (NAb).

    Time frame: Up to 2 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Sep 2026, 12 months later.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's planned 12 months is below that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2025
First posted
Aug 15, 2025
StartEst.
Aug 31, 2025
Primary completionEst.
Sep 30, 2026
CompletionEst.
Sep 30, 2028
Last update
Aug 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07124793
Responsible party
Sponsor
First posted
Aug 15, 2025
Start date
Aug 31, 2025 (estimated)
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Aug 15, 2025

Study contacts

Xiaodong Sun
Contact
xiaodong.sun@innoventbio.com
0512-69566088-8095

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363 · Bevacizumab

Start the discussion